Influence of dosing interval on immune-related adverse events and infusion reaction of nivolumab and pembrolizumab
Not Applicable
Recruiting
- Conditions
- eoplasmsNeoplasmsD009369
- Registration Number
- JPRN-jRCT1030230268
- Lead Sponsor
- none none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Patients treated with nivolumab monotherapy or pembrolizumab monotherapy at Kitasato University Hospital from April 1, 2019, to March 31, 2023
Exclusion Criteria
(i) Patients who switched from the old regimen to the new regimen
(ii) Patients who could not continue more than 2 courses of the old regimen when only the old regimen was administered
(iii) Patients with missing data in the survey items
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method